4.7 Review

Acute Heart Failure Syndromes

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2008.10.041

关键词

heart; failure; decompensated; acute; syndromes

资金

  1. Abbott
  2. Astellas
  3. Bayer
  4. AstraZeneca
  5. Corthera
  6. Debiopharm
  7. Errekappa Terapeutici
  8. EKR Therapeutics
  9. GlaxoSmithKline
  10. Johnson Johnson
  11. Medtronic
  12. Merck
  13. Nile
  14. Novartis
  15. Otsuka
  16. PeriCor
  17. PDL BioPharma
  18. Scios Inc
  19. Solvay Pharmaceuticals
  20. Sigma-Tau
  21. Biogen Idec
  22. Palatin Technologies

向作者/读者索取更多资源

Heart failure resulting in hospitalization represents a significant and growing health care burden. Heterogeneity characterizes this group in terms of mode of presentation, pathophysiology, and prognosis. The vast majority of patients symptomatically improve during hospitalization; however, their early post-discharge rehospitalization and mortality rates continue to be high. Worsening signs and symptoms, neurohormonal, and renal abnormalities occurring soon after discharge may contribute to these high post-discharge event rates. Currently available assessment modalities combined with recent advances in cardiovascular therapies provide present-day opportunities to improve post-discharge outcomes. Further investigation into pathophysiologic targets and novel approaches to clinical trial design are needed. Improving post-discharge outcomes is the single most important goal in the management of acute heart failure syndromes. (J Am Coll Cardiol 2009; 53: 557-73) (C) 2009 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据